SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-99402"
 

Search: onr:"swepub:oai:DiVA.org:oru-99402" > Overall survival of...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Overall survival of patients with metastatic breast cancer in Sweden : a nationwide study

Valachis, Antonis, 1984- (author)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden,Örebro Univ Hosp, Fac Med & Hlth, Dept Oncol, S-70105 Örebro, Sweden
Carlqvist, Peter (author)
Nordic Market Access AB, S-11359 Stockholm, Sweden
Ma, Yuanjun (author)
Parexel International, Stockholm, Sweden,Parexel Int, S-10359 Stockholm, Sweden
show more...
Szilcz, Máté (author)
Karolinska Institutet
Freilich, Jonatan (author)
Umeå universitet,Avdelningen för medicin,Parexel International, Stockholm, Sweden,Parexel Int, S-10359 Stockholm, Sweden.;Umeå Univ, Dept Publ Hlth & Clin Med, S-90187 Umeå, Sweden
Vertuani, Simona (author)
Novartis Sverige AB, S-16428 Kista, Sweden
Holm, Barbro (author)
Novartis Sverige AB, S-16428 Kista, Sweden
Lindman, Henrik (author)
Uppsala universitet,Experimentell och klinisk onkologi
show less...
 (creator_code:org_t)
2022-05-21
2022
English.
In: British Journal of Cancer. - : Nature Publishing Group. - 0007-0920 .- 1532-1827. ; 127:4, s. 720-725
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Breast cancer is the most common cancer among women in Sweden. Whereas survival for the overall breast cancer population is well-documented, survival of patients with metastatic breast cancer (MBC) is harder to quantify due to the lack of reliable data on disease recurrence in national cancer registers.Methods: This study used machine learning to classify the total MBC population in Sweden diagnosed between 2009 and 2016 using national registers, with the aim to estimate overall survival (OS).Results: The total population consisted of 13,832 patients-2528 (18.3%) had de novo MBC whereas 11,304 (81.7%) were classed as having a recurrent MBC. Median OS for patients with MBC was found to be 29.8 months 95% confidence interval (CI) [28.9, 30.6]. Hormone-receptor (HR)-positive MBC had a median OS of 37.0 months 95% CI [35.9, 38.3] compared to 9.9 months 95% CI [9.1, 11.0] for patients with HR-negative MBC.Conclusion: This study covered the entire MBC population in Sweden during the study time and may serve as a baseline for assessing the effect of new treatment strategies in MBC introduced after the study period.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view